Preview Mode Links will not work in preview mode

Aug 4, 2020

A roundtable discussion with Drs Axel Grothey and Michael J Overman on recent developments in the treatment of colorectal cancer, including the following topics:

  • Biomarker analysis for patients with colorectal cancer (CRC) (00:00)
  • Effect of tumor sidedness on prognosis and response to therapy (4:28)
  • Sequencing of systemic therapy for patients with metastatic CRC (mCRC); selection of patients for therapy with EGFR antibodies (8:51)
  • Role of BRAF mutations and the recently FDA-approved combination of encorafenib and cetuximab for patients with mCRC with a BRAF V600E mutation (17:56)
  • Response to BRAF-targeted therapies in patients with BRAF V600E mutations (28:45)
  • Ongoing investigation of mechanisms of resistance to BRAF-targeted therapies (36:20)
  • Efficacy of immune checkpoint inhibitors pembrolizumab, nivolumab and nivolumab/ipilimumab in patients with mCRC; effect of MSI status on response to immunotherapy (38:11)
  • Effect of POLE mutations and tumor mutation burden (TMB) on response to checkpoint inhibitors; recent approval of pembrolizumab for patients with unresectable or metastatic TMB-high (≥10 mut/Mb) solid tumors (47:36)
  • Potential role of immune checkpoint inhibitors in patients with mCRC who have microsatellite-stable disease (58:32)
  • Integration of TAS-102 and regorafenib in the management of mCRC (1:06:26)
  • Dosing considerations and tolerability of regorafenib; association of tumor cavitation and response to regorafenib (1:13:12)
  • Sequencing of TAS-102 and regorafenib in mCRC (1:16:51)
  • Response to the combination of regorafenib and nivolumab among patients with mCRC (1:22:51)
  • Targeting HER2 in mCRC; activity and side-effect profile of trastuzumab deruxtecan (1:29:39)
  • Novel agents and strategies under investigation for patients with mCRC (1:38:23)

CME information and select publications